| Literature DB >> 34505064 |
Steven H Lin1, Ash A Alizadeh2,3,4, Maximilian Diehn5,6,7, Everett J Moding8,9, Yufei Liu10, Barzin Y Nabet9, Jacob J Chabon9, Aadel A Chaudhuri11, Angela B Hui9, Rene F Bonilla8, Ryan B Ko8, Christopher H Yoo8, Linda Gojenola12, Carol D Jones12, Jianzhong He10, Yawei Qiao10, Ting Xu10, John V Heymach13, Anne Tsao13, Zhongxing Liao10, Daniel R Gomez10,14, Millie Das15,16, Sukhmani K Padda15, Kavitha J Ramchandran15, Joel W Neal15, Heather A Wakelee15, Billy W Loo8.
Abstract
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 patients receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 patients receiving consolidation immune checkpoint inhibition (CICI). Patients with undetectable ctDNA after CRT had excellent outcomes whether or not they received CICI. Among such patients, one died from CICI-related pneumonitis, highlighting the potential utility of only treating patients with MRD. In contrast, patients with MRD after CRT who received CICI had significantly better outcomes than patients who did not receive CICI. Furthermore, the ctDNA response pattern early during CICI identified patients responding to consolidation therapy. Our results suggest that CICI improves outcomes for NSCLC patients with MRD and that ctDNA analysis may facilitate personalization of consolidation therapy.Entities:
Mesh：
Substances：
Year: 2020 PMID： 34505064 PMCID： PMC8425388 DOI： 10.1038/s43018-019-0011-0
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347